MCID: DPH001
MIFTS: 60

Diphtheria

Categories: Blood diseases, Infectious diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Diphtheria

MalaCards integrated aliases for Diphtheria:

Name: Diphtheria 12 74 52 58 54 42 3 15 17 71 32
Corynebacterium Infections 43 71
Corynebacterium Infection 12

Characteristics:

Orphanet epidemiological data:

58
diphtheria
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11405
MeSH 43 D003354
ICD10 32 A36 A36.9
MESH via Orphanet 44 D004165
ICD10 via Orphanet 33 A36.0 A36.1 A36.2 more
UMLS via Orphanet 72 C0012546
Orphanet 58 ORPHA1679
UMLS 71 C0010153 C0012546

Summaries for Diphtheria

MedlinePlus : 42 Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics. The diphtheria, pertussis, and tetanus vaccine can prevent diphtheria, but its protection does not last forever. Children need another dose, or booster, at about age 12. Then, as adults, they should get a booster every 10 years. Diphtheria is very rare in the United States because of the vaccine. Centers for Disease Control and Prevention

MalaCards based summary : Diphtheria, also known as corynebacterium infections, is related to tetanus and allergic hypersensitivity disease, and has symptoms including fever, pruritus and tinnitus. An important gene associated with Diphtheria is HBEGF (Heparin Binding EGF Like Growth Factor), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Iron and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and heart, and related phenotypes are Increased viability with SS1P at EC90 and growth/size/body region

Disease Ontology : 12 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.

CDC : 3 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. CDC recommends vaccines for infants, children, teens and adults to prevent diphtheria.

Wikipedia : 74 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Signs and symptoms may... more...

Related Diseases for Diphtheria

Diseases related to Diphtheria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 tetanus 32.2 IL2RA IL2 IL13 CSF2
2 allergic hypersensitivity disease 30.7 IL3 IL2 IL13 CSF2
3 lymphocytic leukemia 30.5 IL3 IL2RA IL2 CSF2
4 pollen allergy 30.4 IL3RA IL3 IL13
5 leukemia, acute lymphoblastic 30.4 PARP1 IL3RA IL3 CSF2 CD9
6 acquired immunodeficiency syndrome 30.3 IL2RB IL2RA IL2 CSF2 CD9
7 cystitis 30.3 IL2 HBEGF EGF
8 leukemia, acute myeloid 30.3 TFRC IL3RA IL3 IL2 EGF CSF2
9 severe combined immunodeficiency 30.2 IL3 IL2RB IL2RA IL2 IL13 CSF2
10 juvenile rheumatoid arthritis 29.9 IL2RB IL2RA IL2
11 human immunodeficiency virus infectious disease 29.9 IL2RA IL2 CSF2 CD9
12 keratoconjunctivitis 29.9 IL3 IL2 IL13
13 parasitic protozoa infectious disease 29.9 IL2 IL13 CSF2
14 immune deficiency disease 29.7 IL2RB IL2RA IL2 IL13 FURIN CSF2
15 hypereosinophilic syndrome 29.7 IL3 IL2RA IL2 IL13 CSF2
16 hematologic cancer 29.5 IL3RA IL3 IL2RA IL2 CSF2
17 leukemia, chronic lymphocytic 29.4 TFRC IL3RA IL2RA IL2 CSF2
18 psoriasis 29.3 IL2RA IL2 IL13 HBEGF EGF
19 inflammatory bowel disease 29.3 IL3 IL2RB IL2RA IL2 IL13 EGF
20 dermatitis, atopic 29.2 IL3 IL2RB IL2RA IL2 IL13 CSF2
21 renal cell carcinoma, nonpapillary 29.2 IL2RB IL2RA IL2 IL13 EGF CSF2
22 multiple sclerosis 29.1 TFRC IL2RB IL2RA IL2 IL13 CSF2
23 malaria 29.1 TFRC IL3 IL2RB IL2RA IL2 IL13
24 rheumatoid arthritis 29.0 TFRC IL2RB IL2RA IL2 IL13 CSF2
25 cutaneous diphtheria 12.8
26 granulomatous lobular mastitis 11.5
27 pertussis 11.2
28 pseudomembranous conjunctivitis 11.2
29 diphtheritic peritonitis 11.2
30 specific antibody deficiency 11.2
31 poliomyelitis 10.9
32 haemophilus influenzae 10.9
33 measles 10.7
34 scarlet fever 10.6
35 endocarditis 10.6
36 myocarditis 10.6
37 refractory hematologic cancer 10.6 FURIN EEF2
38 refractory hairy cell leukemia 10.5 FURIN EEF2
39 large granular lymphocyte leukemia 10.5 IL2RA CSF2
40 virus associated hemophagocytic syndrome 10.5 IL2RB IL2
41 rubella 10.5
42 mumps 10.5
43 typhoid fever 10.5
44 rheumatoid factor-negative juvenile idiopathic arthritis 10.5 IL2RB IL2RA
45 aztreonam allergy 10.5 IL2 IL13
46 amoxicillin allergy 10.5 IL3RA IL3
47 tonsillitis 10.5
48 diclofenac allergy 10.4 IL3RA IL3
49 atopic keratoconjunctivitis 10.4 IL3 IL2
50 pharyngitis 10.4

Comorbidity relations with Diphtheria via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Diphtheria:



Diseases related to Diphtheria

Symptoms & Phenotypes for Diphtheria

UMLS symptoms related to Diphtheria:


fever, pruritus, tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Diphtheria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with SS1P at EC90 GR00376-A-1 9.02 DNAJC24 DPH1 DPH2 DPH3 FURIN

MGI Mouse Phenotypes related to Diphtheria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 CD9 CSF2 DNAJC24 DPH1 DPH3 EEF2
2 embryo MP:0005380 10.1 CSF2 DNAJC24 DPH1 DPH3 EEF2 FURIN
3 hematopoietic system MP:0005397 10.1 CD9 CSF2 DPH1 DPH2 FURIN IL13
4 immune system MP:0005387 10.03 CD9 CSF2 DPH2 EGF FURIN IL13
5 digestive/alimentary MP:0005381 9.98 DPH1 EGF FURIN IL13 IL2 IL2RA
6 mortality/aging MP:0010768 9.86 CD9 CSF2 DNAJC24 DPH1 DPH2 DPH3
7 integument MP:0010771 9.81 CSF2 DPH1 EGF FURIN HBEGF IL13
8 respiratory system MP:0005388 9.17 CD9 CSF2 DPH1 HBEGF IL13 IL2

Drugs & Therapeutics for Diphtheria

Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
2
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
3
Pentetic acid Approved Phase 4 67-43-6
4
Adalimumab Approved Phase 4 331731-18-1 16219006
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
7
Ixazomib Approved, Investigational Phase 4 1072833-77-2
8 Daratumumab Approved Phase 4 945721-28-8
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Lenalidomide Approved Phase 4 191732-72-6 216326
11
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
12
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
13
Lopinavir Approved Phase 4 192725-17-0 92727
14
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
18
BCG vaccine Investigational Phase 4
19
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
20 Antitoxins Phase 4
21 Interleukin 1 Receptor Antagonist Protein Phase 4
22 Gastrointestinal Agents Phase 4
23 Adjuvants, Immunologic Phase 4
24 Chelating Agents Phase 4
25 Iron Chelating Agents Phase 4
26 Protective Agents Phase 4
27 Anticoagulants Phase 4
28 Calcium, Dietary Phase 4
29 Antidotes Phase 4
30 Fibrinolytic Agents Phase 4
31 Cathartics Phase 4
32 Laxatives Phase 4
33 MF59 oil emulsion Phase 4
34 Anti-Inflammatory Agents Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Aluminum phosphate Phase 4
37 Anti-Bacterial Agents Phase 4
38 Chrysanthemum Phase 4
39 Anti-Infective Agents Phase 4
40 Antiviral Agents Phase 4
41
protease inhibitors Phase 4
42 HIV Protease Inhibitors Phase 4
43 Cytochrome P-450 CYP3A Inhibitors Phase 4
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Cytochrome P-450 CYP3A Inducers Phase 4
46 Anti-Retroviral Agents Phase 4
47 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
48 Reverse Transcriptase Inhibitors Phase 4
49 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
50 Anti-HIV Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 510)
# Name Status NCT ID Phase Drugs
1 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
2 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
3 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
4 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
5 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
6 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
7 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
8 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
9 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
10 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
11 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
12 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
13 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
14 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
15 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
16 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
17 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
18 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
19 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
20 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
21 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
22 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
23 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
24 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
25 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
26 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
27 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
28 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
29 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
30 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
31 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
32 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
33 A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
34 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
35 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
36 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
37 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
38 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
39 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
40 Immunogenicity and Safety Study of GSK Biologicals' Boostrix™ Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years Completed NCT01362322 Phase 4
41 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
42 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
43 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
44 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
45 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
46 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
47 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
48 Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix™ (263855) in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
49 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
50 A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. Completed NCT01250756 Phase 4

Search NIH Clinical Center for Diphtheria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Diphtheria Antitoxin
Equine diphtheria antitoxin

Cochrane evidence based reviews: corynebacterium infections

Genetic Tests for Diphtheria

Anatomical Context for Diphtheria

MalaCards organs/tissues related to Diphtheria:

40
Testes, T Cells, Heart, Skin, Kidney, Liver, B Cells

Publications for Diphtheria

Articles related to Diphtheria:

(show top 50) (show all 14684)
# Title Authors PMID Year
1
Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2018-19 School Year. 61 42
31622283 2019
2
Improved quadruplex real-time PCR assay for the diagnosis of diphtheria. 61 42
31478826 2019
3
Risk factors for diphtheria outbreak in children aged 1-10 years in East Kalimantan Province, Indonesia. 61 42
31723410 2018
4
Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer. 54 61
19916021 2010
5
Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. 54 61
20138048 2010
6
Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. 54 61
19850947 2010
7
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. 54 61
19517064 2009
8
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. 54 61
19818653 2009
9
Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. 54 61
19656414 2009
10
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 54 61
19433964 2009
11
Urine podocyte mRNAs mark progression of renal disease. 54 61
19389856 2009
12
Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. 54 61
19221016 2009
13
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. 54 61
18992290 2009
14
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. 54 61
19344187 2009
15
[Fluorescent derivatives of diphtheria toxin subunit B and their interaction with Vero cells]. 54 61
19877418 2009
16
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. 54 61
19689336 2009
17
Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. 54 61
19996587 2009
18
A novel hairless mouse model on an atopic dermatitis-prone genetic background generated by receptor-mediated transgenesis. 54 61
18686008 2008
19
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. 54 61
18722270 2008
20
Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. 54 61
18599586 2008
21
Optimizing denileukin diftitox (Ontak) therapy. 54 61
18684057 2008
22
De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. 54 61
18383317 2008
23
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. 54 61
18222985 2008
24
Dendritic cells are required for effective cross-presentation in the murine liver. 54 61
18213574 2008
25
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. 54 61
18084721 2008
26
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. 54 61
18297533 2008
27
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I. 54 61
17915215 2008
28
Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. 54 61
18089813 2007
29
Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. 54 61
17603081 2007
30
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. 54 61
17975161 2007
31
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. 54 61
17544998 2007
32
Protective role of macrophages in noninflammatory lung injury caused by selective ablation of alveolar epithelial type II Cells. 54 61
17404282 2007
33
Inhibition of transferrin iron release increases in vitro drug carrier efficacy. 54 61
17239470 2007
34
Endogenous ADP-ribosylation of eukaryotic elongation factor 2 and its 32 kDa tryptic fragment. 54 61
17665640 2007
35
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. 54 61
17187516 2007
36
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. 54 61
17200412 2007
37
A diphtheria toxin receptor deficient in epidermal growth factor-like biological activity. 54 61
17071947 2006
38
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. 54 61
16882709 2006
39
Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. 54 61
16817779 2006
40
Immunotoxins in the treatment of hematologic malignancies. 54 61
17073592 2006
41
Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. 54 61
16908626 2006
42
Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. 54 61
16892061 2006
43
Immunotoxins for targeted cancer therapy. 54 61
17025272 2006
44
Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. 54 61
16645883 2006
45
Endogenous ADP-ribosylation for eukaryotic elongation factor 2: evidence of two different sites and reactions. 54 61
16142694 2006
46
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. 54 61
16595600 2006
47
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. 54 61
16634908 2006
48
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. 54 61
16314943 2006
49
Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. 54 61
16358262 2006
50
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. 54 61
16586495 2006

Variations for Diphtheria

Expression for Diphtheria

Search GEO for disease gene expression data for Diphtheria.

Pathways for Diphtheria

Pathways related to Diphtheria according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 IL3RA IL3 IL2RB IL2RA IL2 IL13
2
Show member pathways
13.43 IL3RA IL3 IL2RB IL2RA IL2 HBEGF
3
Show member pathways
13.35 IL3RA IL3 IL2RB IL2RA IL2 IL13
4
Show member pathways
13.27 IL3RA IL3 IL2RB IL2RA IL2 IL13
5
Show member pathways
13.26 IL3RA IL3 IL2RB IL2RA IL2 EGF
6
Show member pathways
13.22 TXNRD1 IL3RA IL3 IL2RB IL2RA IL2
7
Show member pathways
12.97 IL3RA IL3 IL2RA IL2 HBEGF EGF
8
Show member pathways
12.92 IL3RA IL3 IL2RB IL2RA IL2 EGF
9 12.73 TXNRD1 IL3RA IL3 IL2RB IL2RA IL2
10 12.27 IL2RB IL2RA IL2 CSF2
11
Show member pathways
12.2 IL3 IL2RA IL2 IL13 HBEGF
12
Show member pathways
12.03 IL3RA IL3 IL2RB IL2RA IL2 CSF2
13
Show member pathways
11.89 IL2RB IL2RA IL2
14 11.8 IL3RA IL3 IL2RB IL2RA IL2 CSF2
15 11.74 IL2 IL13 CSF2
16 11.74 IL2RB IL2RA IL2 IL13
17 11.74 IL3RA IL3 IL2RB IL2RA IL2 EGF
18
Show member pathways
11.73 TXNRD1 HBEGF FURIN EEF2 CD9
19
Show member pathways
11.71 IL3 IL2RA IL2 CSF2
20 11.68 IL3RA IL2 CSF2
21 11.66 IL2 IL13 CSF2
22 11.63 TFRC IL3RA IL3 IL2RA CSF2 CD9
23
Show member pathways
11.62 IL2RB IL2RA IL2
24 11.59 IL13 EGF CSF2
25
Show member pathways
11.59 IL3RA IL3 IL2RB IL2RA IL2 IL13
26
Show member pathways
11.57 IL2RB IL2RA IL2
27
Show member pathways
11.53 FURIN EEF2 DPH7 DPH3 DPH2 DPH1
28 11.46 IL2RB IL2RA IL2 IL13
29 11.28 IL2RB IL2RA IL2
30 11.24 IL3 IL2 IL13 CSF2
31 11.18 IL2RA IL2 IL13
32
Show member pathways
11.15 IL2RB IL2RA IL2
33 10.96 IL3 IL2 IL13 EGF CSF2

GO Terms for Diphtheria

Cellular components related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 TFRC IL3 IL2 IL13 HBEGF FURIN
2 extracellular region GO:0005576 9.85 TFRC IL3 IL2 IL13 HBEGF FURIN
3 cell surface GO:0009986 9.8 TFRC IL2RB IL2RA HBEGF FURIN CD9
4 clathrin-coated vesicle membrane GO:0030665 9.54 TFRC HBEGF EGF
5 external side of plasma membrane GO:0009897 9.1 TFRC IL3RA IL2RB IL2RA IL13 CD9
6 interleukin-2 receptor complex GO:0005893 8.96 IL2RB IL2RA

Biological processes related to Diphtheria according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.89 IL3 IL2 HBEGF EGF CSF2
2 immune response GO:0006955 9.88 IL3 IL2RA IL2 IL13 CSF2
3 cytokine-mediated signaling pathway GO:0019221 9.7 IL3RA IL3 IL2RB IL2RA IL2 IL13
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 IL3 HBEGF EGF
5 positive regulation of T cell proliferation GO:0042102 9.63 TFRC IL2RA IL2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 IL3 IL2 IL13 CSF2
7 positive regulation of B cell proliferation GO:0030890 9.58 TFRC IL2 IL13
8 MAPK cascade GO:0000165 9.56 IL3RA IL3 IL2RB IL2RA IL2 HBEGF
9 regulation of regulatory T cell differentiation GO:0045589 9.52 IL2RA IL2
10 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2RA IL2
11 interleukin-2-mediated signaling pathway GO:0038110 9.43 IL2RB IL2RA IL2
12 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2RA IL2
13 peptidyl-diphthamide biosynthetic process from peptidyl-histidine GO:0017183 9.02 DPH7 DPH3 DPH2 DPH1 DNAJC24

Molecular functions related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.25 TXNRD1 TFRC PARP1 IL3RA IL2RB IL2RA
2 cytokine activity GO:0005125 9.56 IL3 IL2 IL13 CSF2
3 interleukin-2 binding GO:0019976 9.16 IL2RB IL2RA
4 growth factor activity GO:0008083 9.02 IL3 IL2 HBEGF EGF CSF2
5 interleukin-2 receptor activity GO:0004911 8.96 IL2RB IL2RA

Sources for Diphtheria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....